Sign In

Login

Password

Forgot Password ? Sign Up

Krónikus mieloid leukémia (Hungarian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Krónikus mieloid leukémia" in Hungarian language version.

refsWebsite
Global rank Hungarian rank
59nih.gov
4th place
11th place
45doi.org
2nd place
8th place
3archive.org
6th place
14th place
2web.archive.org
1st place
1st place
1hematologylibrary.org
low place
low place
1cancer.org
3,680th place
4,026th place

archive.org

cancer.org

doi.org

dx.doi.org

  • Jabbour E, Kantarjian H. (2014. May). „Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management.” (angol nyelven). Am J Hematol. 89 (5), 547-56. o. DOI:10.1002/ajh.23691. PMID 24729196.  
  • Agrawal M, Garg RJ, Cortes J, et al. (2010. April). „Tyrosine kinase inhibitors: the first decade.” (angol nyelven). Curr Hematol Malig Rep. 5 (2), 70-80. o. DOI:10.1007/s11899-010-0045-y. PMID 20425399.  
  • Kantarjian H, O'Brien S, et al. (2012. March). „Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience.” (angol nyelven). Blood. 119 (9), 1981-7. o. DOI:10.1182/blood-2011-08-358135. PMID 22228624.  
  • Santos FP, Quintás-Cardama A. (2011. June). „New drugs for chronic myelogenous leukemia.” (angol nyelven). Curr Hematol Malig Rep. 6 (2), 96-103. o. DOI:10.1007/s11899-011-0079-9. PMID 21327563.  
  • Rohrbacher M, Hasford J. (2009. June). „Epidemiology of chronic myeloid leukaemia (CML).” (angol nyelven). Best Pract Res Clin Haematol. 22 (3), 295-302. o. DOI:10.1016/j.beha.2009.07.007. PMID 19959081.  
  • Huang X, Cortes J, Kantarjian H. (2012. June). „Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.” (angol nyelven). Cancer. 118 (12), 3123-7. o. DOI:10.1002/cncr.26679. PMID 22294282.  
  • Ampatzidou M, Papadhimitriou SI, Goussetis E, Panagiotou JP, Papadakis V, Polychronopoulou S. (2012. August). „Chronic myeloid leukemia (CML) in children: classical and newer therapeutic approaches.” (angol nyelven). Pediatr Hematol Oncol. 29 (5), 389-94. o. DOI:10.3109/08880018.2012.691946. PMID 22690835.  
  • Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. (1984. January). „Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22.” (angol nyelven). Cell. 36 (1), 93-9. o. DOI:10.1016/0092-8674(84)90077-1. PMID 6319012.  
  • Ren R. (2005. March). „Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia.” (angol nyelven). Nat Rev Cancer. 5 (3), 172-83. o. DOI:10.1038/nrc1567. PMID 15719031.  
  • Verstovsek S, Lin H, Kantarjian H, Saglio G, et al. (2002. May). „Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent course.” (angol nyelven). Cancer. 94 (9), 2416-25. o. DOI:10.1002/cncr.10490. PMID 12015767.  
  • Burgstaller S, Reiter A, Cross NC. (2007. May). „BCR-ABL-negative chronic myeloid leukemia.” (angol nyelven). Curr Hematol Malig Rep. 2 (2), 75-82. o. DOI:10.1007/s11899-007-0011-5. PMID 20425354.  
  • Vardiman JW, Thiele J, Arber DA, "et al." (2009. July). „The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.” (angol nyelven). Blood. 114 (5), 937-51.. o. DOI:10.1182/blood-2009-03-209262. PMID 19357394.  
  • Wang SA, Hasserjian RP, Fox PS, et al. (2014. April). „Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.” (angol nyelven). Blood. 123 (17), 2645-51. o. DOI:10.1182/blood-2002-04-1199. PMID 24627528.  
  • Giles FJ, Cortes JE, Kantarjian HM, O'Brien SM. (2004. June). „Accelerated and blastic phases of chronic myelogenous leukemia.” (angol nyelven). Hematol Oncol Clin North Am. 18 (3), 753-74. o. DOI:10.1016/j.hoc.2004.03.005. PMID 15271404.  
  • Hehlmann R, Hochhaus A, Baccarani M; European LeukemiaNet. (2007. July). „Chronic myeloid leukaemia.” (angol nyelven). Lancet. 370 (9584), 342-50. o. DOI:10.1016/S0140-6736(07)61165-9. PMID 17662883.  
  • Garcia-Manero G, Faderl S, O'Brien S, Cortes J, Talpaz M, Kantarjian HM. (2003. August). „Chronic myelogenous leukemia: a review and update of therapeutic strategies.” (angol nyelven). Cancer. 98 (3), 437-57. o. DOI:10.1002/cncr.11520. PMID 12879460.  
  • Schoch C, Schnittger S, Bursch S, Gerstner D, Hochhaus A, Berger U, Hehlmann R, Hiddemann W, Haferlach T. (2002. January). „Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases.” (angol nyelven). Leukemia. 16 (1), 53-9. o. DOI:10.1038/sj/leu/2402329. PMID 11840263.  
  • Landstrom AP, Tefferi A. (2006. March). „Fluorescent in situ hybridization in the diagnosis, prognosis, and treatment monitoring of chronic myeloid leukemia.” (angol nyelven). Leuk Lymphoma. 47 (3), 397-402. o. DOI:10.1080/10428190500353133. PMID 16396761.  
  • Gotlib J, Maxson JE, George TI, Tyner JW. (2013. September). „The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment.” (angol nyelven). Blood. 122 (10), 1707-11. o. DOI:10.1182/blood-2013-05-500959. PMID 23896413.  
  • Vardiman JW, Harris NL, Brunning RD (2002). „The World Health Organization (WHO) classification of the myeloid neoplasms” (angol nyelven). Blood. 100 (7), 2292–302. o. DOI:10.1182/blood-2002-04-1199. PMID 12239137.  
  • Santos FP, Kantarjian H, Quintás-Cardama A, Cortes J. (2011. November-December). „Evolution of therapies for chronic myelogenous leukemia.” (angol nyelven). Cancer J. 17 (6), 465-76. o. DOI:10.1097/PPO.0b013e31823dec8d. PMID 22157290.  
  • Chronic Myeloid Leukemia Trialists' Collaborative Group. (1997. November). „Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group.” (angol nyelven). J Natl Cancer Inst. 89 (21), 1616-20. o. DOI:10.1093/jnci/89.21.1616. PMID 9362160.  
  • Baccarani M, Cortes J, Pane F, et al. (2009. December). „Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.” (angol nyelven). J Clin Oncol. 27 (35), 6041-51. o. DOI:10.1200/JCO.2009.25.0779. PMID 19884523.  
  • Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. (2000. September). „Structural mechanism for STI-571 inhibition of abelson tyrosine kinase.” (angol nyelven). Science. 289 (5486), 1938-42. o. DOI:10.1126/science.289.5486.1938. PMID 10988075.  
  • Kantarjian H, Sawyers C, Hochhaus A, et al. (2002. February). „Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.” (angol nyelven). N Engl J Med. 346 (9), 645-52. o. DOI:10.1056/NEJMoa011573. PMID 11870241.  
  • O'Brien SG, Guilhot F, Larson RA, et al. (2003. March). „Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.” (angol nyelven). N Engl J Med. 348 (11), 994-1004. o. DOI:10.1056/NEJMoa022457. PMID 12637609.  
  • Druker BJ, Guilhot F, O'Brien SG, et al. (2006. December). „Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.” (angol nyelven). N Engl J Med. 355 (23), 2408-17. o. DOI:10.1056/NEJMoa062867. PMID 17151364.  
  • Cowan-Jacob SW, Guez V, Fendrich G, Griffin JD, Fabbro D, Furet P, Liebetanz J, Mestan J, Manley PW. (2004. March). „Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment.” (angol nyelven). Mini Rev Med Chem. 4 (3), 285-99. o. DOI:10.2174/1389557043487321. PMID 15032675.  
  • O'Hare T, Walters DK, Stoffregen EP, et al. (2005. June). „In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.” (angol nyelven). Cancer Res. 65 (11), 4500-5. o. DOI:10.1158/0008-5472.CAN-05-0259. PMID 15930265.  
  • Kantarjian H, Shah NP, Hochhaus A, et al. (2010. June). „Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.” (angol nyelven). N Engl J Med. 362 (24), 2260-70. o. DOI:10.1056/NEJMoa1002315. PMID 20525995.  
  • Weisberg E, Manley PW, Breitenstein W, et al. (2005. February). „Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.” (angol nyelven). Cancer Cell. 7 (2), 129-41. o. DOI:10.1016/j.ccr.2005.01.007. PMID 15710326.  
  • Larson RA, Hochhaus A, Hughes TP, et al. (2012. October). „Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.” (angol nyelven). Leukemia. 26 (10), 2197-203. o. DOI:10.1038/leu.2012.134. PMID 22699418.  
  • Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, et al. (2002. August). „Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.” (angol nyelven). Blood. 100 (3), 1014-8. o. DOI:10.1182/blood.V100.3.1014. PMID 12130516.  
  • Soverini S, Hochhaus A, Nicolini FE, et al. (2011. August). „BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.” (angol nyelven). Blood. 118 (5), 1208-15. o. DOI:10.1182/blood-2010-12-326405. PMID 21562040.  
  • Baccarani M, Deininger MW, Rosti G, et al. (2013. August). „European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.” (angol nyelven). Blood. 122 (6), 872-84. o. DOI:10.1182/blood-2013-05-501569. PMID 23803709.  
  • Oehler VG, Gooley T, Snyder DS, et al. (2007. February). „The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia.” (angol nyelven). Blood. 109 (4), 1782-9. o. DOI:10.1182/blood-2006-06-031682. PMID 17062727.  
  • Jabbour E, Cortes J, Santos FP, et al. (2011. March). „Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations.” (angol nyelven). Blood. 117 (13), 3641-7. o. DOI:10.1182/blood-2010-08-302679. PMID 21156844.  
  • Kühr T, Burgstaller S, Apfelbeck U, et al. (2003. May). „A randomized study comparing interferon (IFN alpha) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML).” (angol nyelven). Leuk Res. 27 (5), 405-11. o. DOI:10.1016/S0145-2126(02)00223-0. PMID 12620292.  
  • Mahon FX, Réa D, Guilhot J, et al. (2010. November). „Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.” (angol nyelven). Lancet Oncol. 11 (11), 1029-35. o. DOI:10.1016/S1470-2045(10)70233-3. PMID 20965785.  
  • Gambacorti-Passerini C, Antolini L, Mahon FX, et al. (2011. April). „Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib.” (angol nyelven). J Natl Cancer Inst. 103 (7), 553-61. o. DOI:10.1093/jnci/djr060. PMID 21422402.  
  • Hasford J, Pfirrmann M, Hehlmann R, et al. (1998. June). „A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.” (angol nyelven). J Natl Cancer Inst. 90 (11), 850-8. o. DOI:10.1093/jnci/90.11.850. PMID 9625174.  
  • Deininger MW. (2008. January). „Chronic myeloid leukemia: an historical perspective.” (angol nyelven). Hematology Am Soc Hematol Educ Program. 2008, 418. o. DOI:10.1182/asheducation-2008.1.418. PMID 19074119.  
  • Kampen KR. (2012. January). „The discovery and early understanding of leukemia.” (angol nyelven). Leuk Res. 36 (1), 6-13. o. DOI:10.1016/j.leukres.2011.09.028. PMID 22033191.  
  • Rowley JD. (1973. June). „Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining.” (angol nyelven). Nature. 243 (5405), 290-3. o. DOI:10.1038/243290a0. PMID 4126434.  
  • Iqbal N, Iqbal N. (2014. May). „Imatinib: a breakthrough of targeted therapy in cancer.” (angol nyelven). Chemother Res Pract. 2014, 357027. o. DOI:10.1155/2014/357027. PMID 24963404.  

hematologylibrary.org

bloodjournal.hematologylibrary.org

nih.gov

ncbi.nlm.nih.gov

  • Karbasian Esfahani M, Morris EL, Dutcher JP, Wiernik PH. (2006. May). „Blastic phase of chronic myelogenous leukemia.” (angol nyelven). Curr Treat Options Oncol. 7 (3), 189-99. o. PMID 16615875.  
  • Jabbour E, Kantarjian H. (2014. May). „Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management.” (angol nyelven). Am J Hematol. 89 (5), 547-56. o. DOI:10.1002/ajh.23691. PMID 24729196.  
  • Agrawal M, Garg RJ, Cortes J, et al. (2010. April). „Tyrosine kinase inhibitors: the first decade.” (angol nyelven). Curr Hematol Malig Rep. 5 (2), 70-80. o. DOI:10.1007/s11899-010-0045-y. PMID 20425399.  
  • Kantarjian H, O'Brien S, et al. (2012. March). „Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience.” (angol nyelven). Blood. 119 (9), 1981-7. o. DOI:10.1182/blood-2011-08-358135. PMID 22228624.  
  • Santos FP, Quintás-Cardama A. (2011. June). „New drugs for chronic myelogenous leukemia.” (angol nyelven). Curr Hematol Malig Rep. 6 (2), 96-103. o. DOI:10.1007/s11899-011-0079-9. PMID 21327563.  
  • Fausel C. (2007. May). „Targeted chronic myeloid leukemia therapy: seeking a cure.” (angol nyelven). J Manag Care Pharm. 12 (8 Suppl A), 8-12. o. PMID 17970609.  
  • Rohrbacher M, Hasford J. (2009. June). „Epidemiology of chronic myeloid leukaemia (CML).” (angol nyelven). Best Pract Res Clin Haematol. 22 (3), 295-302. o. DOI:10.1016/j.beha.2009.07.007. PMID 19959081.  
  • Brincker H. (1982. September). „Population-based age- and sex-specific incidence rates in the 4 main types of leukaemia.” (angol nyelven). Scand J Haematol. 29 (3), 241-9. o. PMID 6959254.  
  • Huang X, Cortes J, Kantarjian H. (2012. June). „Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.” (angol nyelven). Cancer. 118 (12), 3123-7. o. DOI:10.1002/cncr.26679. PMID 22294282.  
  • Ampatzidou M, Papadhimitriou SI, Goussetis E, Panagiotou JP, Papadakis V, Polychronopoulou S. (2012. August). „Chronic myeloid leukemia (CML) in children: classical and newer therapeutic approaches.” (angol nyelven). Pediatr Hematol Oncol. 29 (5), 389-94. o. DOI:10.3109/08880018.2012.691946. PMID 22690835.  
  • Preston DL, Kusumi S, Tomonaga M, et al. (1994. February). „Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950-1987.” (angol nyelven). Radiat Res. 137 (2 Suppl), s68-97. o. PMID 8127953.  
  • Nowell PC. (2007. August). „Discovery of the Philadelphia chromosome: a personal perspective.” (angol nyelven). J Clin Invest. 117 (8), 2033-5. o. PMID 17671636.  
  • Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. (1984. January). „Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22.” (angol nyelven). Cell. 36 (1), 93-9. o. DOI:10.1016/0092-8674(84)90077-1. PMID 6319012.  
  • Ren R. (2005. March). „Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia.” (angol nyelven). Nat Rev Cancer. 5 (3), 172-83. o. DOI:10.1038/nrc1567. PMID 15719031.  
  • Melo JV. (1996. May). „The molecular biology of chronic myeloid leukaemia.” (angol nyelven). Leukemia. 10 (5), 751-6. o. PMID 8656667.  
  • Saglio G, Pane F, Gottardi E, et al. (1996. February). „Consistent amounts of acute leukemia-associated P190BCR/ABL transcripts are expressed by chronic myelogenous leukemia patients at diagnosis.” (angol nyelven). Blood. 87 (3), 1075-80. o. PMID 8562932.  
  • Verstovsek S, Lin H, Kantarjian H, Saglio G, et al. (2002. May). „Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent course.” (angol nyelven). Cancer. 94 (9), 2416-25. o. DOI:10.1002/cncr.10490. PMID 12015767.  
  • Burgstaller S, Reiter A, Cross NC. (2007. May). „BCR-ABL-negative chronic myeloid leukemia.” (angol nyelven). Curr Hematol Malig Rep. 2 (2), 75-82. o. DOI:10.1007/s11899-007-0011-5. PMID 20425354.  
  • Vardiman JW, Thiele J, Arber DA, "et al." (2009. July). „The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.” (angol nyelven). Blood. 114 (5), 937-51.. o. DOI:10.1182/blood-2009-03-209262. PMID 19357394.  
  • Wang SA, Hasserjian RP, Fox PS, et al. (2014. April). „Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.” (angol nyelven). Blood. 123 (17), 2645-51. o. DOI:10.1182/blood-2002-04-1199. PMID 24627528.  
  • Giles FJ, Cortes JE, Kantarjian HM, O'Brien SM. (2004. June). „Accelerated and blastic phases of chronic myelogenous leukemia.” (angol nyelven). Hematol Oncol Clin North Am. 18 (3), 753-74. o. DOI:10.1016/j.hoc.2004.03.005. PMID 15271404.  
  • Kantarjian HM, Dixon D, Keating MJ, Talpaz M, Walters RS, McCredie KB, Freireich EJ. (1988. April). „Characteristics of accelerated disease in chronic myelogenous leukemia.” (angol nyelven). Cancer. 61 (7), 1441-6. o. PMID 3162181.  
  • Savage DG, Szydlo RM, Goldman JM. (1997. January). „Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period.” (angol nyelven). Br J Haematol. 96 (1), 111-6. o. PMID 9012696.  
  • Hehlmann R, Hochhaus A, Baccarani M; European LeukemiaNet. (2007. July). „Chronic myeloid leukaemia.” (angol nyelven). Lancet. 370 (9584), 342-50. o. DOI:10.1016/S0140-6736(07)61165-9. PMID 17662883.  
  • Garcia-Manero G, Faderl S, O'Brien S, Cortes J, Talpaz M, Kantarjian HM. (2003. August). „Chronic myelogenous leukemia: a review and update of therapeutic strategies.” (angol nyelven). Cancer. 98 (3), 437-57. o. DOI:10.1002/cncr.11520. PMID 12879460.  
  • Schoch C, Schnittger S, Bursch S, Gerstner D, Hochhaus A, Berger U, Hehlmann R, Hiddemann W, Haferlach T. (2002. January). „Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases.” (angol nyelven). Leukemia. 16 (1), 53-9. o. DOI:10.1038/sj/leu/2402329. PMID 11840263.  
  • Landstrom AP, Tefferi A. (2006. March). „Fluorescent in situ hybridization in the diagnosis, prognosis, and treatment monitoring of chronic myeloid leukemia.” (angol nyelven). Leuk Lymphoma. 47 (3), 397-402. o. DOI:10.1080/10428190500353133. PMID 16396761.  
  • Gotlib J, Maxson JE, George TI, Tyner JW. (2013. September). „The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment.” (angol nyelven). Blood. 122 (10), 1707-11. o. DOI:10.1182/blood-2013-05-500959. PMID 23896413.  
  • Vardiman JW, Harris NL, Brunning RD (2002). „The World Health Organization (WHO) classification of the myeloid neoplasms” (angol nyelven). Blood. 100 (7), 2292–302. o. DOI:10.1182/blood-2002-04-1199. PMID 12239137.  
  • Santos FP, Kantarjian H, Quintás-Cardama A, Cortes J. (2011. November-December). „Evolution of therapies for chronic myelogenous leukemia.” (angol nyelven). Cancer J. 17 (6), 465-76. o. DOI:10.1097/PPO.0b013e31823dec8d. PMID 22157290.  
  • Chronic Myeloid Leukemia Trialists' Collaborative Group. (1997. November). „Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group.” (angol nyelven). J Natl Cancer Inst. 89 (21), 1616-20. o. DOI:10.1093/jnci/89.21.1616. PMID 9362160.  
  • Biggs JC, Szer J, Crilley P, et al. (1992. September). „Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BuCy2.” (angol nyelven). Blood. 80 (1), 1352-7. o. PMID 1515648.  
  • Baccarani M, Cortes J, Pane F, et al. (2009. December). „Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.” (angol nyelven). J Clin Oncol. 27 (35), 6041-51. o. DOI:10.1200/JCO.2009.25.0779. PMID 19884523.  
  • Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. (2000. September). „Structural mechanism for STI-571 inhibition of abelson tyrosine kinase.” (angol nyelven). Science. 289 (5486), 1938-42. o. DOI:10.1126/science.289.5486.1938. PMID 10988075.  
  • Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB. (1996. May). „Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.” (angol nyelven). Nat Med. 2 (5), 561-6. o. PMID 8616716.  
  • Kantarjian H, Sawyers C, Hochhaus A, et al. (2002. February). „Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.” (angol nyelven). N Engl J Med. 346 (9), 645-52. o. DOI:10.1056/NEJMoa011573. PMID 11870241.  
  • O'Brien SG, Guilhot F, Larson RA, et al. (2003. March). „Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.” (angol nyelven). N Engl J Med. 348 (11), 994-1004. o. DOI:10.1056/NEJMoa022457. PMID 12637609.  
  • Druker BJ, Guilhot F, O'Brien SG, et al. (2006. December). „Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.” (angol nyelven). N Engl J Med. 355 (23), 2408-17. o. DOI:10.1056/NEJMoa062867. PMID 17151364.  
  • Cowan-Jacob SW, Guez V, Fendrich G, Griffin JD, Fabbro D, Furet P, Liebetanz J, Mestan J, Manley PW. (2004. March). „Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment.” (angol nyelven). Mini Rev Med Chem. 4 (3), 285-99. o. DOI:10.2174/1389557043487321. PMID 15032675.  
  • O'Hare T, Walters DK, Stoffregen EP, et al. (2005. June). „In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.” (angol nyelven). Cancer Res. 65 (11), 4500-5. o. DOI:10.1158/0008-5472.CAN-05-0259. PMID 15930265.  
  • Kantarjian H, Shah NP, Hochhaus A, et al. (2010. June). „Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.” (angol nyelven). N Engl J Med. 362 (24), 2260-70. o. DOI:10.1056/NEJMoa1002315. PMID 20525995.  
  • Weisberg E, Manley PW, Breitenstein W, et al. (2005. February). „Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.” (angol nyelven). Cancer Cell. 7 (2), 129-41. o. DOI:10.1016/j.ccr.2005.01.007. PMID 15710326.  
  • Larson RA, Hochhaus A, Hughes TP, et al. (2012. October). „Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.” (angol nyelven). Leukemia. 26 (10), 2197-203. o. DOI:10.1038/leu.2012.134. PMID 22699418.  
  • Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, et al. (2002. August). „Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.” (angol nyelven). Blood. 100 (3), 1014-8. o. DOI:10.1182/blood.V100.3.1014. PMID 12130516.  
  • Soverini S, Hochhaus A, Nicolini FE, et al. (2011. August). „BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.” (angol nyelven). Blood. 118 (5), 1208-15. o. DOI:10.1182/blood-2010-12-326405. PMID 21562040.  
  • Baccarani M, Deininger MW, Rosti G, et al. (2013. August). „European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.” (angol nyelven). Blood. 122 (6), 872-84. o. DOI:10.1182/blood-2013-05-501569. PMID 23803709.  
  • Oehler VG, Gooley T, Snyder DS, et al. (2007. February). „The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia.” (angol nyelven). Blood. 109 (4), 1782-9. o. DOI:10.1182/blood-2006-06-031682. PMID 17062727.  
  • Jabbour E, Cortes J, Santos FP, et al. (2011. March). „Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations.” (angol nyelven). Blood. 117 (13), 3641-7. o. DOI:10.1182/blood-2010-08-302679. PMID 21156844.  
  • Silver RT, Woolf SH, Hehlmann R, et al. (1999. September). „An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology.” (angol nyelven). Blood. 94 (5), 1517-36. o. PMID 10477676.  
  • Kühr T, Burgstaller S, Apfelbeck U, et al. (2003. May). „A randomized study comparing interferon (IFN alpha) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML).” (angol nyelven). Leuk Res. 27 (5), 405-11. o. DOI:10.1016/S0145-2126(02)00223-0. PMID 12620292.  
  • Mahon FX, Réa D, Guilhot J, et al. (2010. November). „Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.” (angol nyelven). Lancet Oncol. 11 (11), 1029-35. o. DOI:10.1016/S1470-2045(10)70233-3. PMID 20965785.  
  • Gambacorti-Passerini C, Antolini L, Mahon FX, et al. (2011. April). „Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib.” (angol nyelven). J Natl Cancer Inst. 103 (7), 553-61. o. DOI:10.1093/jnci/djr060. PMID 21422402.  
  • Sokal JE, Cox EB, Baccarani M, et al. (1984. April). „Prognostic discrimination in "good-risk" chronic granulocytic leukemia.” (angol nyelven). Blood. 63 (4), 789-99. o. PMID 6584184.  
  • Hasford J, Pfirrmann M, Hehlmann R, et al. (1998. June). „A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.” (angol nyelven). J Natl Cancer Inst. 90 (11), 850-8. o. DOI:10.1093/jnci/90.11.850. PMID 9625174.  
  • Deininger MW. (2008. January). „Chronic myeloid leukemia: an historical perspective.” (angol nyelven). Hematology Am Soc Hematol Educ Program. 2008, 418. o. DOI:10.1182/asheducation-2008.1.418. PMID 19074119.  
  • Geary CG. (2000. July). „The story of chronic myeloid leukaemia.” (angol nyelven). Br J Haematol. 110 (1), 2-11. o. PMID 10930974.  
  • Kampen KR. (2012. January). „The discovery and early understanding of leukemia.” (angol nyelven). Leuk Res. 36 (1), 6-13. o. DOI:10.1016/j.leukres.2011.09.028. PMID 22033191.  
  • Rowley JD. (1973. June). „Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining.” (angol nyelven). Nature. 243 (5405), 290-3. o. DOI:10.1038/243290a0. PMID 4126434.  
  • Iqbal N, Iqbal N. (2014. May). „Imatinib: a breakthrough of targeted therapy in cancer.” (angol nyelven). Chemother Res Pract. 2014, 357027. o. DOI:10.1155/2014/357027. PMID 24963404.  

web.archive.org